Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program

被引：22

作者：

Mazurek, Michal ^{[1
]}

Teutsch, Christine ^{[2
]}

Diener, Hans-Christoph ^{[3
]}

Dubner, Sergio J. ^{[4
]}

Halperin, Jonathan L. ^{[5
]}

Ma, Chang-Sheng ^{[6
]}

Rothman, Kenneth J. ^{[7
]}

Paquette, Miney ^{[8
]}

Zint, Kristina ^{[9
]}

Franca, Lionel Riou ^{[10
]}

Lu, Shihai ^{[11
]}

Bartels, Dorothee B. ^{[12
]}

Huisman, Menno V. ^{[13
]}

Lip, Gregory Y. H. ^{[14
,15
]}

机构：

[1] Silesian Med Univ, Congenital Heart Dis & Electrotherapy, Dept Cardiol, Silesian Ctr Heart Dis, Zabrze, Poland

[2] Boehringer Ingelheim Int GmbH, Therapeut Area Cardiometab, Dept Clin Dev & Med Affairs, Ingelheim, Germany

[3] Univ Duisburg Essen, Dept Neurol, Essen, Germany

[4] Clin & Maternidad Suizo Argentina, Buenos Aires, DF, Argentina

[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[6] Capital Med Univ, Beijing AnZhen Hosp, Atrial Fibrillat Ctr, Cardiol Dept, Beijing, Peoples R China

[7] RTI Hlth Solut, Res Triangle Pk, NC USA

[8] Boehringer Ingelheim GmbH & Co KG, Dept Med, Burlington, ON, Canada

[9] Boehringer Ingelheim Int GmbH, Global Epidemiol Dept, Ingelheim, Germany

[10] Sanofi Aventis, Chilly Mazarin, France

[11] Boehringer Ingelheim Pharmaceut Inc, Biostat & Data Sci Dept, 90 E Ridge POB 368, Ridgefield, CT 06877 USA

[12] Hannover Med Sch, Hannover, Germany

[13] Leiden Univ, Med Ctr, Dept Thrombosis & Hemostasis, Leiden, Netherlands

[14] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England

[15] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England

来源：

AMERICAN HEART JOURNAL | 2019年 / 218卷

关键词：

ATRIAL-FIBRILLATION; MORTALITY RISKS; WARFARIN; STROKE; EVENTS;

D O I：

10.1016/j.ahj.2019.08.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

GLORIA-AF is a large, ongoing, prospective, global registry program run in 3 phases, assessing long-term safety and effectiveness of dabigatran etexilate (dabigatran) in patients with newly diagnosed atrial fibrillation (AF) in clinical practice. This report provides the final analysis of 2-year clinical outcomes of the full cohort of 4873 patients prescribed dabigatran and followed for a mean of 18.0 +/- 9.4 months out of the 15,308 eligible patients enrolled in Phase II (2011-2014). The overall incidence rates per 100 person-years were: stroke 0.65 (95% CI 0.48-0.87), major bleeding 0.97 (0.76-1.23) and myocardial infarction (MI) 0.50 (0.35.0.69), with observed event rates broadly consistent in all study regions, which confirms the sustained safety and effectiveness of dabigatran over 2 years of observation in clinical practice.

引用

页码：123 / 127

页数：5

共 12 条

[1] Additional Events in the RE-LY Trial [J].

Connolly, Stuart J. ;

Wallentin, Lars ;

Yusuf, Salim .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (15) :1464-1465

[2] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[3] STANDARD DISTANCE IN UNIVARIATE AND MULTIVARIATE-ANALYSIS [J].

FLURY, BK ;

RIEDWYL, H .

AMERICAN STATISTICIAN, 1986, 40 (03) :249-251

[4] Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation [J].

Graham, David J. ;

Reichman, Marsha E. ;

Wernecke, Michael ;

Hsueh, Hui ;

Izem, Rima ;

Southworth, Mary Ross ;

Wei, Yuqin ;

Liao, Jiemin ;

Goulding, Margie R. ;

Mott, Katrina ;

Chillarige, Yoganand ;

MaCurdy, Thomas E. ;

Worrall, Chris ;

Kelman, Jeffrey A. .

JAMA INTERNAL MEDICINE, 2016, 176 (11) :1662-1671

[5] Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation [J].

Graham, David J. ;

Reichman, Marsha E. ;

Wernecke, Michael ;

Zhang, Rongmei ;

Southworth, Mary Ross ;

Levenson, Mark ;

Sheu, Ting-Chang ;

Mott, Katrina ;

Goulding, Margie R. ;

Houstoun, Monika ;

MaCurdy, Thomas E. ;

Worrall, Chris ;

Kelman, Jeffrey A. .

CIRCULATION, 2015, 131 (02) :157-164

[6] Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation [J].

Huisman, Menno V. ;

Lip, Gregory Y. H. ;

Diener, Hans C. ;

Dubner, Sergio J. ;

Halperin, Jonathan L. ;

Ma, Chang S. ;

Rothman, Kenneth J. ;

Teutsch, Christine ;

Zint, Kristina ;

Ackermann, Diana ;

Clemens, Andreas ;

Bartels, Dorothee B. .

AMERICAN HEART JOURNAL, 2014, 167 (03) :329-334

[7] Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation [J].

Larsen, Torben Bjerregaard ;

Gorst-Rasmussen, Anders ;

Rasmussen, Lars Hvilsted ;

Skjoth, Flemming ;

Rosenzweig, Mary ;

Lip, Gregory Y. H. .

AMERICAN JOURNAL OF MEDICINE, 2014, 127 (07) :650-+

[8] Myocardial Ischemic Events in 'Real World' Patients with Atrial Fibrillation Treated with Dabigatran or Warfarin [J].

Larsen, Torben Bjerregaard ;

Rasmussen, Lars Hvilsted ;

Gorst-Rasmussen, Anders ;

Skjoth, Flemming ;

Rosenzweig, Mary ;

Lane, Deirdre A. ;

Lip, Gregory Y. H. .

AMERICAN JOURNAL OF MEDICINE, 2014, 127 (04) :329-+

[9]

Lash T.L., 2010, Applying Quantitative Bias Analysis to Epidemiologic Data

[10] Patient outcomes using the European label for dabigatran A post-hoc analysis from the RE-LY database [J].

Lip, Gregory Y. H. ;

Clemens, Andreas ;

Noack, Herbert ;

Ferreira, Jorge ;

Connolly, Stuart J. ;

Yusuf, Salim .

THROMBOSIS AND HAEMOSTASIS, 2014, 111 (05) :933-942

← 1 2 →